On May 5, 2025, JP Morgan's analyst Chris Schott made a noteworthy update on Biogen (BIIB, Financial), maintaining a 'Neutral' rating while lowering the price target. The revised price target has been adjusted from USD 185.00 to USD 175.00, reflecting a 5.41% decrease. This adjustment highlights a shift in expectations for the company's market performance.
Despite the downward adjustment in the price target, the 'Neutral' rating suggests that JP Morgan predicts a stable performance for Biogen (BIIB, Financial) without significant upward or downward momentum in its stock value. Investors following Biogen (BIIB) may want to consider these updated insights as they assess their portfolios.
The current price target adjustment and maintained rating indicate that JP Morgan does not foresee any immediate drastic changes in Biogen's (BIIB, Financial) market standing. The analysis comes amidst various market dynamics that analysts and investors are closely monitoring.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $173.53 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 41.12% from the current price of $122.97. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.40, suggesting a upside of 71.91% from the current price of $122.97. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
